DERM

DERM EBITDA Growth

257.49%TTM

Period ending:

DERM TTM EBITDA YoY %%
DERM TTM EBITDA YoY %405.17%-1120.82%
2016-09-302026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

DERM ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 38 observations from Sep 30, 2016 to Jun 30, 2026.

Journey Medical Corp EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
257.4916%
0.9763%
60.374%
94.7174%
-120.4264%
-213.9905%
-537.064%
-127.9712%
118.0913%
103.9647%
108.287%
72.4699%
-176.78%
-83.2304%
-42.3807%
-242.5232%
-93.9713%
-323.9943%
-282.6658%
87.4785%
90.4921%
106.1397%
75.5109%
69.4806%
39.6765%
-6.2854%
30.7222%
34.4068%
31.8218%
25.8515%
-332.9365%
-444.6363%
-973.1443%
-393.1366%
5.0155%
7.5753%
65.1417%
8.1996%

Compare ebitda growth

All DERM financial metrics · DERM stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.